8-K: Current report filing
Published on November 8, 2019
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported): November 8, 2019 (November 7, 2019)
APOLLO MEDICAL HOLDINGS, INC.
(Exact name of registrant as specified in its charter)
Delaware |
001-37392 |
95-4472349 |
||
(State or Other Jurisdiction |
(Commission File |
(I.R.S. Employer |
||
of Incorporation) |
Number) |
Identification Number) |
||
1668 S. Garfield Avenue, 2nd Floor, Alhambra, CA 91801
(Address of principal executive offices) (zip code)
(626) 282-0288
(Registrant’s telephone number, including area code)
N/A
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
¨ |
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|
¨ |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
|
¨ |
Precommencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
|
¨ |
Precommencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
|
Securities registered pursuant to Section 12(b) of the Act:
Title of each class |
Trading Symbol(s) |
Name of each exchange on which registered |
Common Stock |
AMEH |
Nasdaq Capital Market |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).
Emerging growth company ¨
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨
Item 2.02 |
Results of Operations and Financial Condition. |
|
On November 7, 2019, Apollo Medical Holdings, Inc. (the “Company”) issued a press release regarding its results of operations and financial condition for the quarter ended September 30, 2019 (the “Original Release”), which incorrectly omitted inclusion of a line item for the current portion of its long-term debt from its condensed consolidated balance sheets as of September 30, 2019 and December 31, 2018. On November 7, 2019, the Company issued a corrective press release (the “Corrective Release”) to include the line item for the current portion of its long-term debt on its condensed consolidated balance sheets as of September 30, 2019 and December 31, 2018 as reported in the Original Release. Copies of the Original Release and the Corrective Release are furnished as Exhibit 99.1 and Exhibit 99.2 to this Current Report on Form 8-K.
In accordance with General Instruction B.2 of Form 8-K, the information furnished pursuant to this Item 2.02, including Exhibit 99.1 furnished herewith, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.
Item 9.01 |
Financial Statements And Exhibits |
|
(d) |
Exhibits. |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
APOLLO MEDICAL HOLDINGS, INC. |
||
Dated: November 8, 2019 |
By: |
/s/ Thomas S. Lam, M.D. |
|
Name:
Title:
|
Thomas S. Lam, M.D.
Co-Chief Executive Officer
|
|